Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions [5]

Leukemia

Volumn 21, Issue 8, 2007, Pages 1827-1828

  Tefferi, A ^a   Lasho, T L ^a   Mesa, R A ^a   Pardanani, A ^a   Ketterling, R P ^a   Hanson, C A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR 1; ERYTHROPOIETIN; HYDROXYUREA; JANUS KINASE 2; LENALIDOMIDE; PROTEIN KINASE B;

ADULT; AGED; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CASE REPORT; CELL CYCLE ARREST; CHROMOSOME DELETION 5; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DRUG ERUPTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE FREQUENCY; HUMAN; LETTER; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; PHOSPHORYLATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UPREGULATION;

EID: 34447634117     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404711     Document Type: Letter

References (8)

1. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
2. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
3. Tefferi A, Cortes; J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164.
4. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 2006; 20: 2063-2064.
5. Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586-588.
6. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141.
7. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
8. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849-858.